2026-09-01 18:35:39 UTC / 路透社
作者：丹尼尔·维斯纳
2026年9月1日 美国东部时间下午6:35 更新，距发稿35分钟前
2024年4月9日，美国伊利诺伊州卡本代尔阿拉莫妇女诊所内，药物流产首步用药米非司酮的包装盒。路透社/伊夫林·霍克斯坦/档案照片
9月1日（路透社）—— 佛罗里达州和德克萨斯州提起的旨在全国范围内严格限制堕胎药物米非司酮使用的诉讼，已被一名联邦法官暂停，等待唐纳德·特朗普政府完成对该药物安全性的审查。
美国得克萨斯州沃斯堡联邦法官里德·奥康纳周一表示，由于提起诉讼的共和党州总检察长与正在进行审查的美国食品药品监督管理局（FDA）已同意搁置此案，暂停诉讼是合理的。
订阅《每日案卷》新闻简报，将最新法律资讯直接发送至您的收件箱，开启您的清晨资讯之旅。[点击此处注册]。
广告 · 滚动继续阅读
奥康纳同时驳回了生产米非司酮并已介入诉讼的制药商GenBioPro和Danco实验室提出的驳回诉讼动议。这位由共和党总统乔治·W·布什任命的法官，将诉讼暂停至12月1日或FDA完成审查两者中较早的时间点。
这场于去年12月提起的诉讼，挑战了FDA在2000年首次批准米非司酮的决定，以及民主党总统巴拉克·奥巴马和乔·拜登政府时期出台的扩大该药物可及性的相关规定，其中包括2023年一项允许通过邮寄方式配发米非司酮的规则。今年4月，另一名法官暂停了路易斯安那州针对该项规则提起的独立诉讼。
广告 · 滚动继续阅读
德克萨斯州总检察长肯·帕克斯顿、佛罗里达州总检察长詹姆斯·尤特迈尔的办公室，以及GenBioPro和Danco实验室，均未在周二立即回应置评请求。
FDA于去年首次宣布对米非司酮展开审查，这种药物被用于美国超过60%的堕胎手术。据悉，该审查已被推迟至11月中期选举之后。
自2022年美国最高法院推翻堕胎宪法权利以来，美国已有近半数州禁止或严格限制堕胎服务。这一举措推动了药物流产的激增，并引发了一系列围绕堕胎药物可及性的法律争端。
药物流产是一种双药联合疗法，先服用米非司酮，再服用米索前列醇，用于在怀孕前10周内终止妊娠。
共有五个州提起了三起独立诉讼，这些诉讼普遍声称，FDA自首次批准米非司酮以来，未对其安全性和有效性进行彻底评估，且忽视了服药女性面临的风险。
绝大多数主流医学团体，以及FDA在过去四分之一个世纪的不同时期均表示，按照说明服用米非司酮是安全有效的，严重不良事件极为罕见。
广告 · 滚动继续阅读
本报记者丹尼尔·维斯纳纽约奥尔巴尼报道；比尔·伯克罗特编辑
我们的报道准则：路透社信托原则
US states’ lawsuit seeking to curb abortion drug access paused for now
2026-09-01 18:35:39 UTC / Reuters
By Daniel Wiessner
September 1, 2026 6:35 PM UTC Updated 35 mins ago
Boxes of Mifepristone, the first pill in a medical abortion, are seen at Alamo Women’s Clinic in Carbondale, Illinois, U.S., April 9, 2024. REUTERS/Evelyn Hockstein/File Photo
Sept 1 (Reuters) – A federal judge paused a lawsuit by Florida and Texas seeking to severely limit access to the abortion pill mifepristone nationwide while President Donald Trump’s administration completes a review of the drug’s safety.
U.S. District Judge Reed O’Connor in Fort Worth, Texas, said on Monday that because the states’ Republican attorneys general and the U.S. Food and Drug Administration, which is conducting the review, had agreed to put the case on hold, it was reasonable to do so.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
O’Connor also rejected a motion by drugmakers GenBioPro and Danco Laboratories, which make mifepristone and have intervened in the lawsuit, to dismiss the case. The judge, an appointee of Republican President George W. Bush, paused the lawsuit until the sooner of December 1 or when the FDA completes its review.
The lawsuit filed last December challenges the FDA’s initial 2000 approval of mifepristone and regulations adopted under Democratic Presidents Barack Obama and Joe Biden expanding access to the drug, including a 2023 rule allowing mifepristone to be dispensed through the mail. A judge in April put on hold a separate lawsuit by the state of Louisiana challenging that regulation.
Advertisement · Scroll to continue
The offices of Texas Attorney General Ken Paxton and Florida Attorney General James Uthmeier, and GenBioPro and Danco, did not immediately respond to requests for comment on Tuesday.
The FDA first announced the review of mifepristone, which is used in more than 60% of U.S. abortions, last year. The study has reportedly been delayed until after the November midterm elections.
Nearly half of U.S. states have banned or severely restricted access to abortion since the U.S. Supreme Court rolled back the constitutional right to undergo the procedure in 2022. That has driven a surge in medication abortion and spurred a series of legal battles over access to the drugs.
Medication abortion is a two-drug regimen consisting of mifepristone followed by misoprostol used to terminate a pregnancy within the first 10 weeks.
Five states have filed three separate lawsuits, which generally claim the FDA has failed to thoroughly evaluate the safety and effectiveness of mifepristone since its initial approval and disregarded the risks to the women who take it.
Most major medical groups, and the FDA at various times over the last quarter-century, have said that mifepristone is safe and effective when taken as directed and that serious adverse events are rare.
Advertisement · Scroll to continue
Reporting by Daniel Wiessner in Albany, New York; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
发表回复